Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).

4510Background: The HCRN GU16-260 trial reported on the efficacy and toxicity of nivo monotherapy in treatment naive clear cell RCC (Cohort A) and the efficacy of nivo/ipi salvage therapy in pts wi...